Author

K. Huhtinen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2

Frequent Co-Authors

J. Hynninen· 3 shared J. Oikkonen· 3 shared K. Lavikka· 3 shared O. Carpen· 3 shared S. Hautaniemi· 3 shared Y. Li· 3 shared A. Virtanen· 2 shared K. Kaipio· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Hynninen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

L1 retrotransposition is regulated post-transcriptionally In High-Grade Serous Ovarian Cancer

B. Pradhan, K. Zhang, Y. Li, K. Lavikka, T. Muranen, K. Huhtinen, R. M. Badge, K. Burns, J. Hynninen, S. Hietanen, J. Oikkonen, S. Hautaniemi, L. Kauppi

The paper investigates L1 retrotransposition in HGSC, finding that despite high L1 mRNA expression, only a third of tumors show somatic insertions, with variability in retrotransposition frequency and patterns.

bioRxiv · Sep 27, 2022 · PreprintCancer Biology

Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients

A. Lahtinen, K. Lavikka, Y. Li, A. Virtanen, S. Jamalzadeh, K. Huhtinen, O. Carpen, S. Hietanen, A. Häkkinen, J. Hynninen, J. Oikkonen, S. Hautaniemi

This study identifies three evolutionary states of ovarian high-grade serous carcinoma using whole-genome sequencing and links them to distinct therapeutic targets.

bioRxiv · Aug 30, 2022Cancer Biology

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

W. Senkowski, L. Gall-Mas, M. M. Falco, Y. Li, K. Lavikka, M. C. Kriegbaum, J. Oikkonen, D. Bulanova, E. J. Pietras, K. Vossgröne, Y.-J. Chen, E. P. Erkan, M. K. Gronning Hog, I. M. Larsen, T. Lamminen, , K. Wennerberg

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

bioRxiv · Apr 21, 2022Cancer Biology

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

A. N. Cvrljevic, U. Butt, K. Huhtinen, T. Gronroos, C. Bockelman, H. Lassus, K. Kaipio, A. Ristimaki, T. Arsiola, T. D. Laajala, D. Connolly, O. Carpen, J. Pouwels, J. Westermarck

The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.

bioRxiv · Mar 31, 2021Cancer Biology